Tivozanib hydrochloride bulk supplier for pharma manufacturers

Tivozanib Hydrochloride Suppliers & Bulk Manufacturers

Available Forms: Capsules

Available Strengths: 0.89 mg, 1.34 mg

Reference Brands: Fotivda (USA/EU)

Category: Oncology Cancer Care

Tivozanib is an oral vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor used in the treatment of advanced renal cell carcinoma (RCC). It works by blocking the VEGF receptors involved in tumor angiogenesis, thereby slowing or stopping the growth of cancer cells. Tivozanib hydrochloride is available in Capsules and strengths such as 0.89 mg, 1.34 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Tivozanib hydrochloride is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Technical Specifications & Supply Details
Lead Time 7 to 60 days (depending on batch size & schedule)
MOQ As per manufacturer’s batch size
COA Available with every batch
Regulatory Dossier / DMF Available upon request
Export Documentation FSC, COA, Manufacturing License, Product Permission
Standards IP, BP, USP
Certifications WHO-GMP, EU-GMP, USFDA (as applicable)

Tivozanib hydrochloride can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

📘 Sourcing Guide
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing

Frequently Asked Questions

Tivozanib hydrochloride is used for the treatment of advanced renal cell carcinoma (RCC) in adults, particularly in cases where the disease has progressed following other cancer therapies.

Tivozanib hydrochloride is made from the active ingredient Tivozanib, a potent and selective inhibitor of VEGF receptors, combined with hydrochloride to form its salt.

The trade name of Tivozanib hydrochloride is Fotivda.

Tivozanib hydrochloride is manufactured by AVEO Oncology and EUSA Pharma.

The generic name is Tivozanib hydrochloride.

The brand name is Fotivda.

Tivozanib hydrochloride is manufactured in countries including the United States, the United Kingdom, and Ireland by AVEO Oncology and EUSA Pharma for global cancer treatment markets.

Yes, Tivozanib hydrochloride is available with DMF and other regulatory documents such as COA and MSDS. These can be provided upon request for qualified buyers.

Absolutely. Sample requests are accepted for formulation trials and quality checks. Please submit an enquiry to initiate the process.

Our manufacturing partners are GMP-certified and comply with ISO and WHO standards, ensuring global quality benchmarks.

Lead times vary based on quantity and destination, but most orders are fulfilled within 1–3 weeks. Express shipping options are available.

Yes, Tivozanib hydrochloride is exported to over 30 countries across Asia, Africa, Europe, and Latin America. We support documentation for customs and regulatory clearance.

Related Products

Momelotinib

Strength:
100 mg, 150 mg, 200 mg

Form: Tablets

Reference Brands: Ojjaara (USA)

View Details
Tovorafenib

Strength:
25 mg/ml

Form: Oral suspension

Reference Brands: Ojemda (USA)

View Details
Nirogacestat

Strength:
50 mg

Form: Tablets

Reference Brands: Generic formulations marketed under different names

View Details
Nintedanib

Strength:
100 mg, 150 mg

Form: Capsules

Reference Brands: Ofev (USA, EU), Vargatef (EU)

View Details
Enquire Now

Quick Response Guaranteed | Verified Suppliers

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.

Please enter the correct answer.
This website uses cookies to ensure you get the best experience. By using our site, you agree to our Privacy Policy.